NeuroSpeak: HSCT in the UK

Is HSCT as a treatment for MS becoming mainstream in the UK? #NeuroSpeak #ClinicSpeak #MSBlog

"The following meeting may be of interest to UK MSologists and pwMS. At least the UK MS community is taking HSCT seriously. With the plummeting mortality related to HSCT maybe it will become routine in many centres? It is looking safer; is it as safe as alemtuzumab treatment? We know already that it is cheaper. I can't see why the NHS won't fund a study to answer the question once and all; what is more effective and cost-effective HSCT or alemtuzumab?"

Symposium on stem cell poster copy (3) from Gavin Giovannoni

International symposium ahst in ms final programme (1) from Gavin Giovannoni

Labels: , ,